Cipla beats quarterly profit view on strong demand
The Hindu
Cipla beats profit estimates with strong demand for chronic condition drugs, faces supply chain issues for tumour drug.
Cipla, India's third-biggest drugmaker by sales, reported a fourth-quarter profit that beat estimates on Tuesday (May 13, 2025), helped by strong demand for its drugs used to treat chronic conditions, especially respiratory illnesses.
The company's consolidated net profit came in at ₹12.22 billion ($143.5 million) in the January-March period. Analysts, on average, expected ₹10.24 billion, per data compiled by LSEG.
Total revenue increased 9.2% to ₹67.3 billion.
Cipla's U.S. sales are usually driven by its tumour drug Lanreotide, its second-biggest revenue generator. However, the company had warned in October that certain supply chain issues related to the drug would last until the fourth quarter.
India's drugmakers that derive significant revenue from North America through their cheaper version of innovator drugs have been on edge following U.S. President Donald Trump's tariff threat.
The company, earlier this year, said that tariffs should not influence decisions at India's drug companies.
Cipla’s generic drug for cancer gets U.S. FDA nod
India's internet user base reaches 958 million, with 57% from rural areas, highlighting rapid digital adoption across the country.
The Economic Survey reveals a decline in agricultural growth to 3.5% in 2025-26, despite steady foodgrain production increases.
Economic Survey 2025-26 warns unconditional cash transfers risk state finances, impacting fiscal sustainability and medium-term growth.
Economic Survey 2025-26 advocates for tax rationalization on debt-assets to enhance investment in corporate bonds and savings.
Restrictions may also be levied on marketing of infant and toddler milk and beverages to tackle rising obesity
Commercial Vehicles major Tata Motors Ltd. (TML) for the third quarter ended December 31, 2025 reported a 48% fall in consolidated net profit to ₹705 crore as compared with ₹1,355 crore in the year ago period due to one-time impacts of Labour Code and de-merger.
India’s energy gap between supply and demand has dropped to nil by November 2025
India's pharma industry shifts to value-driven approaches, focusing on complex generics, innovation, and expanding medical device exports.
The Economic Survey advocates scrapping MGNREGS, citing structural flaws, while introducing a new rural employment law for improved effectiveness.
The Economic Survey warns that an AI-led correction amid geopolitical tensions could severely impact global financial markets.
Economic Survey key takeaways: Here is a look at the key numbers from the Economic Survey 2025-26 in charts, including GDP, inflation, fiscal deficit and more.
The Economic Survey 2025-26 reveals urban land as "dead capital" due to restrictive regulations and unclear titles, urging better utilization.
India's Economic Survey highlights the need for financial regulators to balance growth and stability amid global uncertainties.